Alhadeff et al., GLP-1 and corticostriatal-limbic circuitry GLP-1 may decrease the rewarding effect of food and drugs of abuse by acting on the mesolimbic pathway (Dossat et al., 2011
Comparator interventions were diverse, including metformin (15 trials), placebo (eight trials), GLP-1 RAs/metformin combination (two trials), metformin/clomifene citrate combination (one trial), metformin/cyproterone acetate combination (one trial), cyproterone acetate/ethinyl estradiol combination (one trial), phentermine/topiramate combination (one trial), and calorie-restricted diet (one trial)
For long-term stability, store IGF-1 LR3 at -20C
severe, persistent abdominal pain is a stop-and-seek-care signal
Returns are not accepted due to FDA regulations governing prescription medication handling